A Phase 2/3 interventional study of Teplizumab and Placebo in Type 1 Diabetes Mellitus, sponsored by MacroGenics. Completed at 115 sites in 16 countries. Open to participants aged 8 Years to 35 Years. Per ClinicalTrials.gov, last updated 2023-12-05.
Sponsored by MacroGenics · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.
Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is the only one that started in 2006, is the only one in phase 2/3, and was the 1st registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Argentina, Australia and 17 more countries
Ages 1–25
Abdullah Kars · Sites in Turkey
Ages 18–45
By country, each count listing its studies:
teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 8 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 4 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2006.
This study's enrollment of 554 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 60 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 8 most frequent:
MacroGenics is the lead sponsor of 42 studies on the registry; 4 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 11 (65%) have results posted.
MacroGenics has 4 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this protocol is to assess the efficacy, tolerability, and safety of MGA031 when administered according to 3 different MGA031 dosing regimens in children and adults with recent-onset (diagnosis within past 12 weeks) type 1 diabetes mellitus. All regimens will be administered as an addition to insulin and other standard of care treatments. Efficacy will be defined primarily by the capacity of MGA031 to markedly reduce typical insulin requirements while maintaining relatively normal blood sugar levels.
Other studies involving the study drug use the name hOKT3γ1 (Ala-Ala). MGA031, a humanized monoclonal antibody, is the name used for hOKT3γ1 (Ala-Ala) that is produced by MacroGenics, Inc. The United States Adopted Name (USAN) for MGA031 is teplizumab.
The Protégé Study - A Multinational Clinical Trial of MGA031 for Preserving the Capability to Produce Insulin, Reducing Insulin Usage and Improving Blood Sugar Levels in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following criteria:
One positive result on testing for any of the following antibodies:
Subject must be in one of the following age groups:
Exclusion Criteria:
Subjects must have none of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Full dose of teplizumab IV for 14 days, repeated at Week 26
Biological: Teplizumab
One third full dose of teplizumab IV for 14 days, repeated at Week 26
Biological: Teplizumab
Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
Biological: Teplizumab
Placebo IV dosing daily for 14 days repeated at Week 26
Drug: Placebo
Full dose of teplizumab IV for 14 days, repeated at Week 26
Biological: Teplizumab
Daily IV dosing for 14 days, repeated at Week 26
Also known as: MGA031
Daily IV dosing for 14 days, repeated at Week 26
Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.
This is a composite endpoint is based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5% at 52 weeks after randomization.
Time frame: 52 weeks after randomization
Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.
This is a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%
Time frame: 52 weeks after first dose
Mean HbA1c Change From Baseline in Segment 2
Comparison among study treatments of average change from baseline HbA1C. This endpoint will be assessed in a hierarchical manner only if the composite primary endpoint shows a statistically significant difference between arms
Time frame: 52 weeks after randomization
Mean HbA1c Change From Baseline in Segment 1
The average change in HbA1c levels after dosing.
Time frame: 52 weeks after first dose
Change From Baseline in C-peptide Area Under the Curve (AUC) in Segment 2
Comparison among study treatments on the AUC of C-peptide secretory responses following a mixed meal eaten by the subject
Time frame: 104 weeks after randomization
Change From Baseline in C-peptide AUC in Segment 1
AUC of C-peptide secretory responses following a mixed meal eaten by the subject
Time frame: 104 weeks after first dose
Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5%
Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%.
Time frame: 104 weeks after randomization
Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5%
Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%.
Time frame: 104 weeks after first dose
Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%.
Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 7.0%.
Time frame: at 52 weeks after randomization
Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%.
Composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 7.0%.
Time frame: 52 weeks after first dose
Mean HbA1c Change From Baseline in Segment 2
Comparison among study treatments of the average change from baseline in HbA1c.
Time frame: at 104 weeks after randomization
Mean HbA1c Change From Baseline in Segment 1
Comparison among study treatments of the average change from baseline in HbA1c.
Time frame: 104 weeks after first dose
| Milestone | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| Started | 38 | 0 | 0 | 0 | 0 |
| Completed | 35 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Milestone | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| Started | 0 | 209 | 102 | 106 | 99 |
| Full analysis set (fas) population | 0 | 207 | 102 | 106 | 98 |
| Safety population | 0 | 207 | 102 | 106 | 98 |
| Completed | 0 | 183 | 90 | 97 | 92 |
| Not completed | 0 | 26 | 12 | 9 | 7 |
| Withdrew: Adverse event | 0 | 3 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 11 | 5 | 2 | 5 |
| Withdrew: Withdrawal by subject | 0 | 10 | 6 | 7 | 2 |
| Withdrew: Other | 0 | 2 | 0 | 0 | 0 |
| Milestone | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| Started | 35 | 183 | 90 | 97 | 92 |
| Completed | 35 | 183 | 90 | 97 | 92 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
This is a composite endpoint is based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5% at 52 weeks after randomization.
| Participants | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%. | — | 41 | 14 | 22 | 20 |
This is a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%
| Participants | Open-label Herold Regimen |
|---|---|
| Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%. | 11 |
Comparison among study treatments of average change from baseline HbA1C. This endpoint will be assessed in a hierarchical manner only if the composite primary endpoint shows a statistically significant difference between arms
| percentage of HbA1c | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| Mean HbA1c Change From Baseline in Segment 2 | — | -0.42 ± 2.285 | -0.34 ± 2.196 | -0.36 ± 2.132 | -0.43 ± 2.668 |
The average change in HbA1c levels after dosing.
| percent HbA1c | Open-label Herold Regimen |
|---|---|
| Mean HbA1c Change From Baseline in Segment 1 | 0.25 ± 2.053 |
Comparison among study treatments on the AUC of C-peptide secretory responses following a mixed meal eaten by the subject
| min*nmol/L | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| Change From Baseline in C-peptide Area Under the Curve (AUC) in Segment 2 | — | -0.18 ± 0.355 | -0.27 ± 0.318 | -0.20 ± 0.354 | -0.22 ± 0.428 |
AUC of C-peptide secretory responses following a mixed meal eaten by the subject
| min*nmol/L | Open-label Herold Regimen |
|---|---|
| Change From Baseline in C-peptide AUC in Segment 1 | -0.45 ± 0.451 |
Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%.
| Participants | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5% | — | 17 | 6 | 10 | 9 |
Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 6.5%.
| Participants | Open-label Herold Regimen |
|---|---|
| Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 6.5% | 5 |
Comparison among study treatments of a composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 7.0%.
| Participants | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%. | — | 60 | 21 | 28 | 24 |
Composite endpoint based on the proportion of subjects who have both a total daily insulin dose \<0.5 U/Kg/day and an HbAlc level 7.0%.
| Participants | Open-label Herold Regimen |
|---|---|
| Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and HbA1c Level of Less Than 7.0%. | 14 |
Comparison among study treatments of the average change from baseline in HbA1c.
| percent of HbA1c | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| Mean HbA1c Change From Baseline in Segment 2 | — | 0.14 ± 2.411 | 0.08 ± 2.261 | 0.04 ± 2.208 | 0.16 ± 2.510 |
Comparison among study treatments of the average change from baseline in HbA1c.
| percentage of HbA1c | Open-label Herold Regimen |
|---|---|
| Mean HbA1c Change From Baseline in Segment 1 | 0.73 ± 2.091 |
Collected over Adverse events (AE), serious adverse events (SAE), and adverse events of special interest (AESI) were collected through Week 52. Only SAE and AESI were collected after Week 53 through Week 104.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-label Herold Regimen | 0/38 (0%) | 6/38 (15.8%) | 38/38 (100%) |
| Double-blind Herold Regimen | 1/207 (0.5%) | 23/207 (11.1%) | 207/207 (100%) |
| Double-blind 33.3% Herold Regimen | 1/102 (1%) | 14/102 (13.7%) | 101/102 (99%) |
| Double-blind Curtailed Herold Regimen | 0/106 (0%) | 12/106 (11.3%) | 105/106 (99.1%) |
| Double-blind Placebo | 0/98 (0%) | 12/98 (12.2%) | 98/98 (100%) |
| Event | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 2/38 | 6/207 | 3/102 | 2/106 | 0/98 |
| GastritisGastrointestinal disorders | 1/38 | 0/207 | 1/102 | 0/106 | 0/98 |
| Cytokine release syndromeImmune system disorders | 1/38 | 0/207 | 0/102 | 0/106 | 0/98 |
| Dengue feverInfections and infestations | 1/38 | 0/207 | 0/102 | 0/106 | 0/98 |
| Hepatitis AInfections and infestations | 1/38 | 0/207 | 0/102 | 0/106 | 0/98 |
| PharyngotonsillitisInfections and infestations | 1/38 | 0/207 | 0/102 | 0/106 | 0/98 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/38 | 1/207 | 1/102 | 1/106 | 1/98 |
| KetonuriaRenal and urinary disorders | 1/38 | 0/207 | 0/102 | 0/106 | 0/98 |
| RashSkin and subcutaneous tissue disorders | 1/38 | 1/207 | 0/102 | 0/106 | 0/98 |
| KeytonuriaRenal and urinary disorders | 1/38 | 0/207 | 0/102 | 0/106 | 0/98 |
| Event | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo |
|---|---|---|---|---|---|
| LymphopeniaBlood and lymphatic system disorders | 36/38 | 152/207 | 67/102 | 81/106 | 17/98 |
| LeukopeniaBlood and lymphatic system disorders | 25/38 | 101/207 | 49/102 | 50/106 | 22/98 |
| Blood bicarbonate decreasedInvestigations | 13/38 | 92/207 | 60/102 | 41/106 | 38/98 |
| Aspartate aminotransferase increasedInvestigations | 17/38 | 73/207 | 28/102 | 37/106 | 33/98 |
| RashSkin and subcutaneous tissue disorders | 17/38 | 65/207 | 44/102 | 37/106 | 11/98 |
| Alanine aminotransferase increasedInvestigations | 16/38 | 71/207 | 26/102 | 31/106 | 17/98 |
| White blood cell count decreasedInvestigations | 15/38 | 86/207 | 32/102 | 41/106 | 18/98 |
| NeutropeniaBlood and lymphatic system disorders | 15/38 | 71/207 | 33/102 | 22/106 | 18/98 |
| Haemoglobin decreasedInvestigations | 14/38 | 66/207 | 29/102 | 34/106 | 32/98 |
| HyponatraemiaMetabolism and nutrition disorders | 8/38 | 64/207 | 35/102 | 38/106 | 34/98 |
Baseline characteristics for age, six, race and ethnicity are from the FAS, which includes only those participants enrolled and receiving study treatment (n=551). There were 3 participants enrolled who were never dosed so they are excluded from the FAS.
| Age, Continuous(years) | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo | Total |
|---|---|---|---|---|---|---|
| Median | 13.5 (10.0 to 34.0) | 17 (8 to 35) | 17 (8 to 34) | 16 (8 to 33) | 17 (8 to 34) | 17 (8 to 35) |
| Age, Customized(Participants) | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo | Total |
|---|---|---|---|---|---|---|
| age 8-11 years | 11 | 31 | 15 | 16 | 15 | 88 |
| age 12-17 years | 16 | 81 | 42 | 44 | 38 | 221 |
| age 18-35 years | 11 | 95 | 45 | 46 | 45 | 242 |
| Sex: Female, Male(Participants) | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 8 | 77 | 40 | 34 | 37 | 196 |
| Male | 30 | 130 | 62 | 72 | 61 | 355 |
| Ethnicity (NIH/OMB)(Participants) | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 14 | 7 | 12 | 5 | 40 |
| Not Hispanic or Latino | 36 | 193 | 95 | 94 | 93 | 511 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 5 | 59 | 28 | 29 | 27 | 148 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 1 | 2 |
| White | 33 | 145 | 74 | 75 | 69 | 396 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 0 | 1 | 1 | 5 |
| Region of Enrollment(participants) | Open-label Herold Regimen | Double-blind Herold Regimen | Double-blind 33.3% Herold Regimen | Double-blind Curtailed Herold Regimen | Double-blind Placebo | Total |
|---|---|---|---|---|---|---|
| Romania | 4 | 7 | 5 | 4 | 4 | 24 |
| United States | 20 | 64 | 32 | 31 | 31 | 178 |
| Czechia | 8 | 12 | 7 | 5 | 6 | 38 |
| Ukraine | 0 | 18 | 10 | 9 | 10 | 47 |
| Spain | 0 | 6 | 3 | 3 | 3 | 15 |
| India | 5 | 59 | 28 | 29 | 28 | 149 |
| Canada | 1 | 6 | 1 | 4 | 1 | 13 |
| Sweden | 0 | 0 | 0 | 1 | 0 | 1 |
| Latvia | 0 | 3 | 1 | 2 | 1 | 7 |
| Poland | 0 | 10 | 5 | 6 | 4 | 25 |
| Mexico | 0 | 9 | 4 | 5 | 4 | 22 |
| Israel | 0 | 11 | 6 | 6 | 6 | 29 |
| Germany | 0 | 2 | 0 | 0 | 0 | 2 |
| Estonia | 0 | 2 | 0 | 1 | 1 | 4 |
Showing the first 100 of 115 sites across 16 countries. Choose a country and city above to see the rest.
Plan to share: No
The record gives a start of Oct 2006, a primary completion of Jun 2010 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2023, 13 years 6 months after primary completion. A results delay was requested in Nov 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teplizumab